Copyright
        ©The Author(s) 2021.
    
    
        World J Hepatol. Jul 27, 2021; 13(7): 731-746
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.731
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.731
| Beta blocker | Initial dose | Goal | Treatment duration | Further guidance | 
| Propranolol | 20–40 mg twice daily | Maximum dosage of 160 mg/day; Or until the resting heart rate of 55–60 beats/min; Maximum dosage of 80 mg/day in patients with ascites | Indefinite | Adapt every 2-3 d until optimal dose is reached; Discontinue during spontaneous bacterial peritonitis, hyponatremia (Na < 125 mmol/L) or acute kidney injury; Systolic blood pressure should not decrease below 90 mmHg; EGD for further variceal screening is not needed | 
| Carvedilol | 6.25 mg once daily | Maximum dosage of 12.5 mg/day | Indefinite | Adapt dose after 3 d and increase to 6.25 mg twice daily; Discontinue during spontaneous bacterial peritonitis, hyponatremia (Na < 125mmol/L) or acute kidney injury; Systolic blood pressure should not decrease below 90 mmHg; EGD for further variceal screening is not needed; Potential switch from carvedilol to propranolol in case of new onset of ascites | 
| Nadolol | 20-40 mg once daily | Maximum dosage of 160 mg/day; Or until the resting heart rate of 55–60 beats/min; Maximum dosage of 80 mg/day in patients with ascites | Indefinite | Adapt every 2-3 d until optimal dose is reached; Discontinue during spontaneous bacterial peritonitis, hyponatremia (Na < 125mmol/L) or acute kidney injury; Systolic blood pressure should not decrease below 90 mmHg; EGD for further variceal screening is not needed | 
| Regimen | Dosing | Duration of regimen | Further guidance | 
| Somatostatin | Bolus of 500 μg, followed by 500 μg/h via continuous infusion (6 mg/50 mL, infusion rate of 4.2 mL/h) | 2-5 d | Bolus can be repeated in case of uncontrolled bleeding | 
| Terlipressin | Bolus of 2mg every 4 h for the first 24-48 h, followed by giving bolus of 1mg every 4 h; Or continuous infusion 2 mg/d; maximum 12 mg/d | 2-5 d | Be caution in patients with coronary artery disease, peripheral arterial occlusive disease hyponatremia (< 125 mmol/L), cardiac arrhythmia and severe asthma or chronic occlusive pulmonary disease | 
| Octreotide (somatostatin analogue) | Bolus of 50 μg, followed by 50 μg via continuous infusion | 2-5 d | Bolus can be repeated in case of uncontrolled bleeding | 
- Citation: Pfisterer N, Unger LW, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol 2021; 13(7): 731-746
- URL: https://www.wjgnet.com/1948-5182/full/v13/i7/731.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i7.731

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                        